The Memo: Inmedix Bringing Precision to the Autonomic Nervous System

Under the direction of Co-Founder and CEO Dr. Andrew Holman, Inmedix is advancing a new category of precision diagnostics focused on the autonomic nervous system (ANS), an often overlooked contributor to chronic disease and treatment response variability. Through its FDA-cleared CloudHRVⓇ system, the company is equipping clinicians with a medical-grade, real-time measure of ANS state, enabling a more personalized and data-driven approach to care. Built on decades of clinical research and grounded in rheumatology, Inmedix is positioning ANS measurement as a foundational input in modern medicine, with the potential to reshape how physicians understand and treat complex, chronic conditions.

Origin Story

Inmedix is rooted in Dr. Holman’s decades-long career as a rheumatologist and clinical researcher, where he developed a reputation for tackling some of the most misunderstood conditions in medicine.

“After becoming a physician, I specialized in rheumatology due to its puzzle-solving demands and complex immunology,” Holman said. “On a personal note, I never left a room with a patient crying and maintained relationships with patients for decades. I always believed patients when others didn’t.”

That commitment became especially important in the treatment of fibromyalgia, a condition long dismissed by parts of the medical community.

“The turning point came when I didn’t give up on fibromyalgia patients at a time when the condition was widely dismissed or misunderstood. For decades, women with fibromyalgia were told their symptoms were ‘all in their head’ or attributed to stress, anxiety, hormonal issues, or simply not a clinician’s problem,” he explained.

Driven to better understand these patients, Holman began exploring how the body’s stress response influences chronic disease treatment. His clinical work led to a key insight: a measurable connection between heart rate variability (HRV) and disruption of the ANS, the system that controls the body’s stress response, including functions such as heart rate and immune activity.

Following three prospective clinical trials and the sale of an international patent portfolio to Boehringer Ingelheim, Holman stepped away from the field. But the implications of his research stayed with him.

“Over the next 10 years, I couldn’t sleep at night knowing I held ANS testing technology with potential application to autoimmune disease,” he said. “This drove me out of retirement to found Inmedix.”

Today, the company is headquartered in Seattle, Washington, with an initial focus on the U.S. market and plans for international expansion through its subsidiary, Inmedix UK.

The Current Landscape

Inmedix is entering a large and underserved clinical landscape where treatment outcomes remain inconsistent and difficult to predict.

More than 15 million patients in the U.S. suffer from autoimmune diseases and fibromyalgia, with 75% failing to respond to current treatments and over $10 billion wasted annually, according to the Inmedix team. These conditions disproportionately affect women, who make up roughly 80% of diagnosed patients.

Despite available treatments, outcomes remain unpredictable. In rheumatoid arthritis (RA) alone, three out of four treatments fail to adequately control the disease.

According to peer-reviewed evidence, a critical variable appears to be missing.

“A prominent missing link appears to be the ANS,” he said. “The ability to precisely measure the ANS has been reported to strongly impact how patients react to RA immunosuppressive treatment.”

The ANS regulates the body’s stress response, influencing immune activity, cardiovascular function, sleep, and metabolism. Excessive ANS sympathetic activity (fight-or-flight) contributes to chronic illness, morbidity, and mortality due to metabolic syndromes, sleep, mood, strain on the heart, and impaired immune function.

Holman points to the ANS as an “invisible factor affecting 60 to 80% of primary care complaints,” highlighting its potential role as a foundational driver across a wide range of diseases.

Inside the Innovation

Inmedix’s solution centers on its CloudHRV system, an FDA-cleared diagnostic platform that delivers a precise measurement of ANS state using a five-minute ECG.

During an assessment, patients lie supine while ECG leads are applied to the wrists and ankles. The system captures approximately 350 heartbeats over five minutes, transmitting the data to a secure cloud environment where beat-to-beat variability is analyzed through proprietary calculation.

Results are returned to the clinician within seconds, providing immediate, actionable insight for clinical decision-making.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-inmedix-bringing-precision-to-the-autonomic-nervous-system